TerminatedPhase 2NCT03736720
Liposomal Irinotecan, Fluorouracil and Leucovorin in Treating Patients With Refractory Advanced High Grade Neuroendocrine Cancer of Gastrointestinal, Unknown, or Pancreatic Origin
Studying Neuroendocrine carcinoma of pancreas
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Roswell Park Cancer Institute
- Principal Investigator
- Renuka Iyer, MDRoswell Park Cancer Institute
- Intervention
- Fluorouracil(drug)
- Enrollment
- 11 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2019 – 2024
Study locations (2)
- Roswell Park Cancer Institute, Buffalo, New York, United States
- Stony Brook Cancer Center, Stony Brook, New York, United States
Collaborators
Ipsen
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03736720 on ClinicalTrials.govOther trials for Neuroendocrine carcinoma of pancreas
Additional recruiting or active studies for the same condition.